WO2008004121A2 - Extraits d'ail pour le traitement de l'ostéoporose, et procédé d'extraction correspondant - Google Patents

Extraits d'ail pour le traitement de l'ostéoporose, et procédé d'extraction correspondant Download PDF

Info

Publication number
WO2008004121A2
WO2008004121A2 PCT/IB2007/002094 IB2007002094W WO2008004121A2 WO 2008004121 A2 WO2008004121 A2 WO 2008004121A2 IB 2007002094 W IB2007002094 W IB 2007002094W WO 2008004121 A2 WO2008004121 A2 WO 2008004121A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
bone
extracts
osteoporosis
drrf
Prior art date
Application number
PCT/IB2007/002094
Other languages
English (en)
Inventor
Villoo Morawala Patell
Original Assignee
Avestha Gengraine Technologies Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avestha Gengraine Technologies Pvt. Ltd. filed Critical Avestha Gengraine Technologies Pvt. Ltd.
Publication of WO2008004121A2 publication Critical patent/WO2008004121A2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives

Definitions

  • the invention relates to compositions and methods for preventing, treating, or managing osteoporosis or other related disorders such as bone loss, bone fracture, glucocorticoid induced osteoporosis, Pagets disease, osteoarthritis, peri-prosthetic osteolysis, cartilage degeneration, osteogenesis imperfecta and the like, comprising administration of a prophylactically and therapeutically effective amount of ' Allium sativum plant or extracts thereof to a mammal in need of such therapy.
  • the mammal is human and the compositions comprise of single extract or a combination of extracts thereof.
  • the present invention further relates to extracts which are isolated from Allium sativum, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament.
  • the present invention also relates to the process for preparing the extracts from the bulbs of Allium sativum.
  • Osteoporosis is a skeletal disorder that is characterized by low bone mass and micro- architectural deterioration of bone tissue. Affecting 200 million individuals world-wide, osteoporosis is the most common metabolic bone disorder which leads to an increased level of bone fragility and susceptibility to fracture (Walker-bone, et al. 2002; Lin and Lane, 2004).
  • osteoporosis is categorized as a primary or secondary disease.
  • the latter involves the onset of osteoporosis as a result of an existing condition such as an endocrine disorder, the use of certain medications, a hematopoietic disorder, immobilization, or a nutritional, gastrointestinal or connective tissue disorder (Lin and Lane, 2004).
  • Primary osteoporosis is further subdivided into two types. Type I generally occurs in postmenopausal women and is attributed to loss of gonadal hormone function, such as estrogen deficiency associated with menopause (Lin and Lane, 2004; Simon, 2004).
  • Type II osteoporosis generally called as senile osteoporosis is age-related, affecting both men and women over the age of 60.
  • BMD bone mineral density
  • DEXA dual energy x-ray absorptiometry
  • the World Health Organization has defined osteoporosis as a BMD more than 2.5 standard deviations below the mean of normal, healthy individuals at their peak bone mass (Lin and Lane, 2004; Simon, 2004; Christodoulou and Cooper, 2003).
  • Bone remodeling occurs at specific sites on the bone surface known as basic multicellular units and is carried out by osteoclasts (bone resorption pells) and osteoblasts (bone formation cells) (Tolstoi 2004, Manolagas and Weinstein, 1999).
  • Both osteoblasts and osteoclasts are derived from precursors originating in the bone marrow and the formation and activation of these cells is regulated by cytokines and growth factors also produced in the bone marrow, which are in turn controlled by systemic factors and mechanical stimuli (Manolagas and Weinstein 1999).
  • the bone remodeling cycle is" highly dependent on a delicate balance between regulatory signaling and cellular activity. Loss of the capacity to recruit active osteoblasts or deactivate osteoclasts results in a net bone loss and can lead to the onset of osteoporosis.
  • Activated vitamin D is a signaling molecule that is largely involved in the regulation of intestinal calcium absorption Tsai, et al., 1984). Therefore, poor vitamin D metabolism leads to a decrease in intestinal calcium absorption and results in PTH signaling, by the endocrine system, to withdraw calcium from the bones. Over time, this continuous removal of calcium from the bones leads to decreased bone mass and development of osteoporosis.
  • antiresorptive drugs which slow the progressive thinning of bone
  • bone forming drugs which help to rebuild the skeleton
  • drugs with a more complex mechanism of action drugs used to treat osteoporosis.
  • calcium and vitamin D supplements might also be prescribed to ensure adequate intake and to ensure maximum effectiveness of the drug therapy.
  • Bisphosphonates inhibit bone resorption. They are currently the first choice of treatment in a variety of bone metabolism disorders characterised by high bone resorption.
  • SERM Selective estrogen receptor modulators
  • osteoblasts bone-forming cells
  • cost Forteo costs about $600 a month, and it also must be injected every day. For those reasons, it's generally only prescribed for patients with severe osteoporosis, or who have already had one or more fractures.
  • Allium sativum belongs to the genus Allium and family liliaceae.
  • Garlic is one of the more commonly used health supplements in the world. It is said to be the world's second oldest medicine after Ephedra and is still one of the best and most popular herbal remedies.
  • Garlic best known for it's cardiovascular and lipid-lowering effects, has also been studied for its hypoglycemic effects and now is suggested for Osteoporosis. Osteoclastogenesis is commonly associated with various age-related diseases, including cancer.
  • a member of the tumor necrosis factor, receptor activator of nuclear factor- kappaB (NF-kappaB) ligand (RANKL) has been shown to play a critical role in osteoclast formation and bone resorption.
  • the pathway that activates this transcription factor can be interrupted using phytochemicals found in spices.
  • the diallyl sulfide, S- allylmercaptocysteine and ajoene present in Garlic and its ability to suppress the Nuclear Factor- ⁇ kappa ⁇ B activation pathway has been experimented by Aggarwal and Shishodia in 2004.
  • the effects of oil extract of garlic on different primary and secondary osteoporotic marker changes were tested in an ovariectomized rat model of osteoporosis by Mukherjee et.al. 2004.
  • Garlic could be a promising candidate for further studies on Osteoporosis as there is no literature describing the use of Allium sativum extracts for the treatment of Osteoporosis.
  • the invention relates to compositions and methods for preventing, treating, or managing osteoporosis other related disorders such as bone loss, bone fracture, glucocorticoid induced osteoporosis, Pagets disease, osteoarthritis, peri-prosthetic osteolysis, cartilage degeneration, osteogenesis imperfecta and the like, comprising administration of a prophylactically and therapeutically effective amount of Allium sativum plant or extracts thereof to a mammal in need of such therapy.
  • the mammal is human and the compositions comprise of single extract or a combination of extracts thereof.
  • the present invention further relates to extracts which are isolated from bulbs of Allium sativum plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament.
  • the present invention also relates to the process for preparing the extracts from Allium sativum plant bulbs.
  • the process comprises of:
  • the lyophilized extracts are further taken for cell based and cell free bioassay.
  • compositions/medicaments may contain a pharmaceutically acceptable carrier, excipient, or diluent.
  • the compositions can be included as unit dosage suitable for parenteral, oral, or intravenous administration to a human.
  • the compositions are dietary supplements, food compositions or beverage compositions suitable for human or animal consumption.
  • the invention further describes the biotherapeutic potential of various extracts of Allium sativum as described above, by studying their performance in cell based assay models.
  • Fig 1 Cell viability for Plant Extracts AN29 , AN30 and AN31.
  • FIG 2 CTX release data for plant extracts of the bulbs of Allium sativum for the resorption experiment
  • Fig 3 Cell viability for plant extracts of the bulbs of Allium sativum for the resorption experiment
  • Fig 4 The CTX release for plant extract AN31 for the resorption experiment
  • Fig 5 The cell viability for plant extracts AN31 for the resorption experiment
  • Fig 6 The TRAP activity for plant extracts AN31 for the resorption experiment
  • a method for treating a disease in a mammal which comprises administering to the said mammal an effective non-toxic amount of at least an extract from Allium sativum as defined herein.
  • the mammal is a human being.
  • treating a disease means treating, that is to say, alleviating symptoms of the disease and may also mean managing a disease in the sense of preventing such a disease state either advancing ie getting worse or becoming more invasive, or slowing down the rate of advance of a disease.
  • the mammal is human and the said extract comprises a single extract from a plant part of Allium sativum or a combination of extracts therefrom as detailed herein.
  • the present invention further relates to extracts, which may be isolated from bulbs of the Allium sativum plant, the preparation of such extracts, medicaments comprising such extracts, and the use of these extracts and constituents for the preparation of a medicament.
  • Extracts of the present invention can be isolated from the bulbs of Allium sativum, using conventional organic solvent extraction and supercritical fluid extraction technology.
  • extracts of the invention capable of functioning in a prophylactic or therapeutic manner as outlined herein can be extracted from any Allium sativum plant, depending on the end purpose that is required of the extract.
  • the choice of selected plant material may be of any type but is preferably the bulbs of the Allium sativum plant.
  • the solvent extraction process may be selected from direct types such as extraction from plant parts in soxhlet apparatus or in flasks at room temperature or at higher temperature with polar and/or non-polar solvent(s). Typically, the extraction process is as outlined herein.
  • mouse osteoblastic cells MC3T3 (mouse clavarial osteoblast like cells) were seeded at a density of 20,000 cells in 96 well plates and cultured for one day prior to the addition of the plant extracts.
  • the stock solutions of the extracts dissolved in DMSO were diluted to 3 different concentrations.
  • the cells after addition of the extracts are cultured for 3 days and cell viability is measured by a colorimetric based cell viability assay as exemplified in the detailed description.
  • separate cytotoxicity tests, stability tests and the like can be conducted to evaluate the toxicity of the extracts or compositions ⁇ can be conducted.
  • the therapeutic compositions of the invention will need to meet certain criteria in order to be suitable for human or animal use and to meet the regulatory requirements.
  • standard in-vivo and in vitro tests can be conducted to determine the information about the metabolism and pharmacokinetics of the compositions, including data on the drug- drug interactions where appropriate, which can be used to design human clinical trials.
  • the present invention further contemplates that where toxicity is a factor, for example, in patients who cannot tolerate optimal or standard therapeutic dosages, or in cases where the patient's metabolism is compromised sub-optimal doses would be preferred.
  • osteoclasts are largely derived from CD 14 positive monocytes (J.Haemotol, 1999 JuI; 106(l):167-70). Clonal analysis of haematopoietic cells by surface phenotypes has been used to further identify osteoclast precursor by characterizing osteoclast like cells distinct from other haematopoietic progenitors (Lee et.al; 1992b Muguruma & Lee; 1988). Surface phenotype analysis has shown that human osteoclasts are derived from CD 14 monocytes (Massey & Flanagan, 1999).
  • CD 14 marker is strongly expressed on monocytes, the putative osteoclast precursor in peripheral blood and CD 14 positive monocytes have been selected for osteoclastogenesis. (Clin.Sci (Lond) 2000, Aug, 99(2): 133-40). Determination of the ability of the plant extracts to inhibit osteoclastic bone resorption has been undertaken wherein the potential extracts can be tested for their ability to inhibit these cell activity using a variety of techniques known in art, including, but not limited to, those described herein. In the context of the present, invention, a plant extract that decreases the activity of the osteoclast cells by atleast 40% in comparison to the control is considered capable of inhibiting osteoclastic bone resorption.
  • a method of screening of plant extracts suitable for inclusion in the therapeutic compositions comprising (a) providing one or more plant extract isolated with a specific solvent (b) analyzing the one or more extract for their inhibitory activity on bone resorption (c) selecting the extracts that decrease the activity of bone resorption by atleast 40%, as plant extracts suitable for inclusion in the therapeutic compositions.
  • Bone particle-based assays Bone particles, obtained by grinding of 45Ca- or [3H] proline-labeled bones, are cultured with osteoclasts. 45Ca or [3H] release is measured at the end of the cultures (Oreffo et al. 1988). Bone slice assay. This widely used assay is based on the observation that isolated osteoclasts make resorption pits on slices of devitalised dentine or bone (Boyde et all 984) and that these pits resemble Howship's lacunae.
  • Various formats may be used if the potential extracts are to be tested against a specific set of cultured osteoclast cells.
  • the assays may be adapted in order to facilitate the simultaneous testing of many potential extracts. Such techniques are being constantly developed and the use of such techniques to identify the potential extract activity is considered to be within the scope of the present invention.
  • osteoblast culture systems that have been developed include cultures containing osteoblast or osteoblast-like cells from different species, bones of different ages, and a variety of anatomical sites and pathological states. Systems have also been developed for specific cell populations, such as osteoprogenitor cells and osteocytes. Several recent articles have also discussed various osteoblast cell culture models and provide some critical commentaries about their use (Marie, 1994; Rodan et al. 1994; Gundle & Beresford, 1995, Parfitt,1995; Roby, 1995). In the present invention MC3T3 cell line was used. These cells are murine osteogenic mesenchymal precursor cells, which can be differentiated into osteoblasts by ascorbic acid and beta-gylcerol phosphate.
  • a plant extract that increases activity of the osteoblast cells comprising (a) providing one or more plant extract isolated with a specific solvent (b) analyzing the one or more extract for their activity on bone formation (c) selecting the extracts that promote the activity of bone formation.
  • a colorimetric assay with o-cresolphthalein is commonly used to measure calcification in TCA extracts of cultured bones (Gronowicz et al. 1989).
  • Calcein a fluorescent dye that stains calcium phosphate deposits (Hock et al. 1968), can be used to measure calcification in mineralising cell cultures. Calcification, however, can be increased by bone damage or death (Ramp & Neuman, 1971). Therefore, the bone should also be checked by histological examination. Several histological methods can be used to assess bone morphology (Malluche & Faugere, 1986).
  • alkaline phosphatase which is simple to measure biochemically.
  • Its expression pattern in osteoblasts Doty & Schofield, 1976; Stein et al. 1996) and its involvement in mineralisation have been extensively documented (Wuthier & Register, 1984).
  • many cell types in bone or marrow stroma contain alkaline phosphatase, such as hypertrophic chondrocytes (Wuthier & Register, 1984) and adipocytes (Beresford et al. 1993), while fibroblastic cells also have a low concentration of this enzyme.
  • the alkaline, phosphatase activity can provide a good indicator of osteoblast cells if the cartilage and marrow are removed by dissection.
  • the present invention evaluates the bone formation that has occurred through Alkaline phosphatase assay and the proliferation that has occurred through Alamar blue assay.
  • Suitable cell lines such as ST2 (mature monocytes and macrophages capable of differentiating into osteoclasts ,MLC-6 (osteoclast like cell line derived from mouse, MC3T3-E1 (mouse calvaria, Sudo et al 1983), MBA- 15 (Clonal marrow stromal cell line ) and the like.
  • Osteoblast cell lines include 2T3 (osteoblast cell line), AHTO, HOBIT cell lines and the like can be used for the cell based assays. These cell lines can be obtained from ATCC or various other commercial sources. The invention premeditates the use of such suitable osteoclast and osteoblast cell lines for conducting the cell based assays.
  • compositions suitable for use in the treatment of Osteoporosis comprising at least one extract as isolated from a Allium sativum, in admixture with a pharmaceutically acceptable carrier.
  • the at least one extract is selected from those listed in Table 1.
  • compositions may comprise of two or more plant extracts of the invention in any concentration, which is capable of giving rise to a therapeutic effect.
  • therapeutic compositions can comprise plant extracts of Allium .substantially devoid of undesirable contaminating compounds. "The plant extracts may have, for example, undergone a number of solvent extraction steps substantially to separate out undesirable components from desirable components such as those alluded to in the examples and aforementioned tables.
  • the invention thus further provides a method for the treatment of Osteoporosis or conditions, which are characterized by increased bone resorption in mammals, including humans, which comprises the use of a clinically useful amount of an extract selected from those listed in Table 1 , in a pharmaceutically useful form, once or several times a day or in any other appropriate schedule for example, orally, or intravenously or by delivery to the lungs in a dry or "wet" spray.
  • the amount of compound of extract required to be effective in the treatment Osteoporosis or conditions, which are characterized by increased bone resorption will, of course, vary with the disease being treated and is ultimately at the discretion of the medical or veterinary practitioner.
  • the factors to be considered include the condition being treated, the route of administration, and nature of the formulation, the mammal's body weight, surface area, age and general condition and the particular compound to be administered.
  • a suitable effective dose of an extract of the invention generally lies in the range of about 500 mg twice daily.
  • Formulations of the present invention for medical use, comprise an extract of the invention together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients.
  • the carrier(s) should be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and substantially non-deleterious to the recipient thereof.
  • the present invention therefore, further provides a pharmaceutical formulation comprising at least one extract selected from those listed in table 1, together with a pharmaceutically acceptable carrier therefore.
  • any pharmaceutical formulation comprising an active extract of the invention can include at least one active extract purified from, an extract derived from Allium species.
  • a pharmaceutical formulation may contain more than one active extract derived from two or more Allium species. .
  • Formulations according to the present invention include those suitable for oral or intravenous administration.
  • Intravenous formulations including at least one extract of the invention and may also be administered in the form of suitable liposomal or niosomal preparations or other suitable delivery vehicle.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glycerol mono-stearate and sodium laury sulphate.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active extracts(s) into association with a carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active extract(s) into association with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product into desired formulations.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, tablets, lozenges, comprising the active ingredient in a flavoured based, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.
  • Each formulation generally contains a predetermined amount of the active extract; as a powder or granules; or a solution or suspension in an aqueous or nonaqueous liquid such as syrup, an elixir, an emulsion or draught and the like.
  • a tablet may be made by compression or moulding optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing an a suitable machine the active extract in a free-flowing form such as a powder or granules, optionally mixed with a binder, (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycolate, cross- linked povidone, cross-linked sodium carboxymethyl cellulose), surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered extract moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide the desired release profile.
  • a syrup may be made by adding the active extract to a concentrated, aqueous solution of a sugar, for example sucrose, to which may also be added any necessary ingredients.
  • Such accessory ingredient(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredients, such as a polyhydric alcohol for example glycerol or sorbitol.
  • the formulations of this invention may further include on or more accessory ingredients) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • accessory ingredients selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • compositions are dietary supplements, food compositions or beverage compositions suitable for human or animal consumption.
  • a comestible that is to say, a foodstuff comprising at least an extract of the invention, typically in dried form, such as in a lyophilized form selected from. those listed in Table 1 herein.
  • the skilled addressee will appreciate that such comestibles may contain more than one extract of the invention and may be used.
  • Such foodstuffs may be used in a prophylactic manner and may contain further extracts having a similar function to the first added extract or further added extracts may be added that have a different prophylactic function.
  • a foodstuff could either comprise extracts that provide for a comestible having a single functional aspect, or a comestible may have a multi-functional prophylactic effect against two or more disease types.
  • the type of foodstuff or comestible to which at least an extract of the invention may be added includes any processed food such as confectionaries, baited products including breads such as loafs, and flat breads such as pitta bread, naan bread and the like, cakes, snack foods such as muesli bars, compressed dried fruit bars, biscuits, dairy products such as yoghurts, milk and milk-based products such as custards, cream, cheese, butter and creme fraiche, simulated dairy food products such as margarine, olive oil-based spreads, and low fat cream substitutes such as Elmlea products, fruit and vegetable juices, aerated drinks, such as carbonated soft drinks and non-aerated drinks such as squashes, soya milk, rice milk and coconut milk and the like, pastas, noodles, vegetable, seed and nut oils, fruited oils such as sunflower oil, rapeseed oil, olive oil, walnut, hazelnut, and sesame seed oil and the like, and frozen confections such as ice creams
  • a suitable effective dose of an extract of the invention to be included in a comestible generally lies in the range 500 mg twice daily.
  • Example 1 Extraction of Allium sativum'.
  • Extraction of Allium sativum bulb was carried out by direct extraction method, at 20 - 85 C in reflux apparatus followed by lyophilization.
  • Various solvents used for extraction are Hexane, 80% Ethanol and Acetone.
  • the extract was concentrated by fitting the flask containing the extract with the empty soxhlet extractor body that in turn was fitted tightly with the water ⁇ cooled condenser. Continuous water flow was maintained and the flask was heated till the solvent from the flask was distilled and collected in the extractor body up to a level. (One inch below the inlet). The temperature was reduced to avoid charring as the volume of the solvent reduced in the flask. The distilled solvent collected in the extractor was transferred to the solvent bottles and label appropriately. The process was continued till only very little solvent was left in the flask and no charring had occurred. The extract in the flask were swirled and were dried under vacuum.
  • Extract ID contains the first six letters of the plant code followed by the part of the plant used. This is followed by type of extraction, extraction temperature, solvent and the percentage of the solvent used. Which is followed by the date, month and year of extraction for the identification of the three extracts, which are the subject matter of the invention.
  • Table 1 Representative extracts of the bulbs of ' Allium sativum a.
  • Example 1 Amount of the solvent - 1000 ml, Amount of plant material - 200 g b.
  • Example B Amount of the solvent - 500 ml, Amount of plant material - 100 g c.
  • Example C Amount of the solvent - 100 ml, Amount of plant material - 2O g
  • the plant extracts were tested in three concentrations to examine the toxicity of the extracts to MC3T3 cells.
  • the stock solutions of the extract were diluted 1:100, 1 :1000 and 1 : 10000 in the medium for the cells.
  • the concentrations have been chosen so that the concentration of DMSO used for making the stock solutions is not higher than 1%.
  • MC3T3 cells were seeded at a density of 20000 cells per well in 96 well plate. The cells were cultured for one day before the plant extracts were added in the three dilutions. The cells were after the addition of the extracts cultured for three days. At the end of the culture period the cell viability was measured by the AlamarBlue assay.
  • AN29 and AN30 are not toxic at either of the dilutions, while AN31 is toxic at dilution 1 :100. Therefore, dilution 1:1000 and 1 :10,000 will be used for the hit screening in the bone resorption assay and in the bone formation assay.
  • Collagen type I makes up >90% of the organic matrix of bone.
  • Collagen type I is composed of linked type I collagen molecules, with the amino- and carboxy-terminal regions of a type I collagen molecule linked to the helical region of adjacent collagen molecules through pyridinium cross-links, deoxypyridinoline (Dpd) and pyridinoline
  • telopeptides consist of short peptide sequences from the helical domain of a type I molecule and the telopeptide region of an adjacent molecule, joined by a pyridinium cross-link (either Pyd or Dpd).
  • telopeptides released from bone are excreted unchanged in urine, and the remainder are metabolized by the liver and kidneys.
  • Commercial assays have been developed for 3 forms of collagen type I telopeptide: NTX, CTX, and ICTP (a slight variant of CTX).
  • the osteoclasts were isolated as CD 14 positive monocytes and differentiated into - osteoclasts for 10-12 days. Hereafter, the osteoclasts were lifted by trypsin, counted and seeded on bovine bone slices at a density of 40000 cells per bone slice. The osteoclasts were seeded on the bone slices for one day before the plant extracts were added. The osteoclasts were hereby allowed to attach and initiate resorption.
  • the plant extracts were added in two concentrations 1:10,000 and 1:100,000 dilutions because the toxicity study in the MC3T3 cells had shown that these concentrations were not toxic to the cells.
  • Bafilomycin is a V-ATPase blocker and it inhibits the osteoclastic bone resorption approximately 80% compared to DMSO (the negative control will be set to 100 % on the chart.
  • the bone resorption experiment was ended after 5 days of incubation and the cell viability was measured by the use of the AlamarBlue assay. Bone resorption was evaluated as the determination of the CTX release.
  • FIG 2 represents CTX release data for plant extracts of the bulbs of Allium sativum for the resorption experiment and Fig 3 represents cell viability for plant extracts of the bulbs of Allium sativum for the resorption experiment.
  • Plant extract AN29 which is Allium sativum extract made with hexane, has a very little effect on bone resorption at dilution 1 :1000 ( ⁇ 40% compared to the control), but not enough to test the extract in the lead characterisation. Extract AN29 are not toxic at either concentration.
  • Plant extract AN30 which is Allium sativum extract made with 80% ethanol, inhibits bone resorption at dilution 1 :1000 ⁇ 50% compared to control.
  • AN30 is toxic at dilution 1 :1000 to the same level ( ⁇ 50% compared to control). Therefore, the inhibitor effect is due to toxicity and AN30 will not be tested further.
  • Plant extract AN31 which is Allium sativum extract made with acetone, inhibits bone resorption for dilution 1 :1000 ⁇ 90% compared to control. The extract is toxic at dilution 1:1000, but to a higher level than the effect on resorption ( ⁇ 70% compared to control). Therefore, extract AN31 will be tested further in bone resorption lead characterisation.
  • MC3T3 cell lines were used for the bone formation studies. These cells are murine osteogenic mesenchymal precursor cells, which can be differentiated into osteoclasts by ascorbic acid and beta-glycerol phosphate.
  • the osteoblasts (MC3T3 cells) were seeded at a density of 75000 cells per well in 24 plates. The cells were culture for one day before the plant extracts were added. Then the osteoblasts were cultured for 14 days in medium supplemented with ascorbic acid and beta-glycerol phosphate (AA and bG) and in the presence of the plant extracts (1 :10,000 and 1:100,000 dilution)
  • BMP-2 bone morpho genie protein -2
  • BMP-2 is used as a positive control, while the treatment without ascorbic avid and beta-glycerol phosphate (without AA and bG) is the negative control.
  • BMP-2 induces the MC3T3 precursor cells to differentiate into osteoblasts and the ALP activity is induced compared to the negative control.
  • the bone resorption experiment was ended after 10 days of incubation and the cell viability was measured by the use of the AlamarBlue assay (figure 5). Bone resorption was evaluated as the determination of the CTX release (figure 4). Furthermore, the osteoclastic marker TRAP was measured (ANSOP007) (figure 6). AN31 inhibit bone resorption completely at dilution 1 :1000 ( ⁇ 95% compared to control). However, the extract is toxic to the cells at this concentration ( ⁇ 60% compared to control). The lead characterisation confirms the result, which were achieved for the hit screening. There is a dose depended inhibition of the resorption for plant extract AN31.
  • Plant extract AN31 from Allium sativum has an effect on bone resorption, which were characterised further by the lead characterisation.
  • the effect on bone resorption of plant extract AN29 and AN30, which is fractionated with hexane and 80% ethanol was too little and the extracts were not selected for further test in the lead characterisation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions et des procédés de prévention, traitement ou prise en charge de l'ostéoporose ou d'états caractérisés par un accroissement de la résorption osseuse, par administration à un mammifère justifiant un tel traitement, d'une quantité prophylactiquement et thérapeutiquement efficace d'ail (Allium sativum) ou d'extraits d'ail. De préférence, le mammifère et un humain, et les compositions comprennent un extrait unique ou une combinaison d'extraits d'ail. L'invention concerne également des extraits isolés à partir d'Allium sativum, l'élaboration de tels extraits, les médicaments contenant ces extraits, et l'utilisation de ces extraits et constituants pour l'élaboration d'un médicament. L'invention concerne enfin le procédé d'élaboration des extraits à partir de diverses parties de la plante.
PCT/IB2007/002094 2006-07-06 2007-07-09 Extraits d'ail pour le traitement de l'ostéoporose, et procédé d'extraction correspondant WO2008004121A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1181/CHE/2006 2006-07-06
IN1181CH2006 2006-07-06

Publications (1)

Publication Number Publication Date
WO2008004121A2 true WO2008004121A2 (fr) 2008-01-10

Family

ID=38894948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002094 WO2008004121A2 (fr) 2006-07-06 2007-07-09 Extraits d'ail pour le traitement de l'ostéoporose, et procédé d'extraction correspondant

Country Status (1)

Country Link
WO (1) WO2008004121A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008102036A1 (fr) * 2007-02-20 2008-08-28 Universidad De Castilla-La Mancha Procédé d'obtention d'un extrait lyophilisé et stable à partir de plantes du genre allium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008102036A1 (fr) * 2007-02-20 2008-08-28 Universidad De Castilla-La Mancha Procédé d'obtention d'un extrait lyophilisé et stable à partir de plantes du genre allium

Similar Documents

Publication Publication Date Title
FI91877B (fi) Menetelmä osseiini-hydroksiapatiittiyhdisteen valmistamiseksi
WO2008004118A2 (fr) Extraits de carthamus tinctoris pour le traitement de l'ostéoporose, et leur procédé d'extraction
US7803844B2 (en) Composition for preventing and/or treating bone disease, physiologically functional or health food containing thereof, and pharmaceutical containing thereof as active ingredients
WO2008016105A1 (fr) Composition pharmaceutique destinée à la prévention et/ou au traitement d'une maladie osseuse, aliment fonctionnel ou aliment diététique contenant la composition, et préparation pharmaceutique contenant la composition en tant que principe actif
JP6272646B2 (ja) ａｘｉａｌ−ｅｑｕａｔｏｒｉａｌ ａｒｙｌ配向のｆｕｒｏｆｕｒａｎ型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品
WO2008084283A2 (fr) Extraits végétaux d'andrographis paniculata destinés à traiter l'ostéoporose et leur procédé d'extraction
WO2009007774A1 (fr) Extraits d'asparagus racemosa pour traiter l'ostéoporose et son procédé d'extraction
Torricelli et al. Intermittent exposure to ethanol vapor affects osteoblast behaviour more severely than estrogen deficiency does: In vitro study on rat osteoblasts
WO2008004026A1 (fr) Extraits de la plante citrus reticulata utilisés dans le traitement de l'ostéoporose et procédé d'extraction associé
WO2008004121A2 (fr) Extraits d'ail pour le traitement de l'ostéoporose, et procédé d'extraction correspondant
WO2008004119A2 (fr) Extraits d'eugenia jambolana pour le traitement de l'ostéoporose, et procédé d'extraction correspondant
WO2008007216A2 (fr) Extraits de plante psoralea corylifolia pour traiter l'ostéoporose et procédé d'extraction associé
WO2008007214A2 (fr) Extraits de plante glycyrrhiza glabra pour traiter l'ostéoporose et procédé d'extraction correspondant
WO2008084282A2 (fr) Extraits végétaux de punica granatum destinés à traiter l'ostéoporose et leur procédé d'extraction
KR101790031B1 (ko) 인삼 추출물, 작약 추출물, 감초 추출물 및 키토산을 유효성분으로 포함하는 폐경 또는 난소절제로 인한 여성 골다공증 예방 또는 치료용 약학적 조성물
US20090280196A1 (en) Cissus quadrangularis plant extracts for treating osteoporosis and the extraction process thereof
WO2008007215A2 (fr) Extraits végétaux de berberis aristata pour le traitement de l'ostéoporose et procédé d'extraction associé
WO2008081233A2 (fr) Extraits végétaux de cissus quandrangularis pour le traitement de l'ostéoporose et procédé d'extraction correspondant
KR101739838B1 (ko) 로가닌을 유효성분으로 함유하는 파골세포 분화 억제용 시약 조성물
US20090317501A1 (en) Pinus Pinea Plant Extracts For Treating Osteoporosis and the Extraction Process Thereof
EP3159003A2 (fr) Composition pour améliorer la croissance osseuse, la prévention de troubles de la résorption osseuse et pour la santé des articulations
KR101756405B1 (ko) 스코폴린을 유효성분으로 함유하는 여성 폐경 후 골다공증 예방 또는 개선용 조성물
US10226477B2 (en) Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin
KR101970353B1 (ko) 몰루긴 및 bmp-2를 포함하는 골 질환의 예방 또는 치료용 조성물
KR20170086006A (ko) 아스타잔틴을 유효성분으로 포함하는 갱년기 질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789534

Country of ref document: EP

Kind code of ref document: A2

WA Withdrawal of international application